Clinical Trials Browser

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Cancer

Prostate Cancer Metastatic

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-sensitive Prostate Cancer

Metastatic Castration-resistant Prostate Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Metastatic Castration-resistant Prostate Cancer

Ovarian Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Advanced Prostate Cancer

NSCLC Harboring NRG1 Fusion

Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Prostatic Neoplasms

Adenocarcinoma, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Clinical Trials

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

MAGNITUDE

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

ARX517

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

OMAHA-003

CELLO-1

MK-5684-004

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

KEYNOTE-365

AMPLITUDE

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Double-DARE

EvoPAR-PR01

CAPItello-281

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

QUEST

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

CONTACT-02

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

P300

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Study to Evaluate CCS1477 in Advanced Tumours

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

KEYLYNK-010

CYCLONE 2

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

EPI-7386

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

PK and Dose Escalation and Expansion Study of DST-2970

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate